Aptevo Provides 3Q26 Business Update Highlighting Growing Momentum for Mipletamig and Reports Third Quarter Financial Results
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Aptevo Therapeutics (NASDAQ:APVO) reported third-quarter financial results and clinical progress for mipletamig in frontline acute myeloid leukemia, a blood cancer. Net loss narrowed to $6.5 million from $7.5 million a year earlier. Cash fell to $8.3 million at September 30, 2026, from $9.8 million at June 30.
Among 14 evaluable patients with TP53-mutated disease receiving mipletamig with venetoclax and azacitidine, 11 achieved complete remission or complete remission with incomplete blood-count recovery. Separately, ten of 47 evaluable frontline patients receiving the combination proceeded to stem cell transplantation. Aptevo reported fewer infusion-related reactions after priming-dose changes and targets RAINIER Phase 1b completion by year-end 2026, with regulatory interaction planned for first-half 2027.
An August financing raised approximately $4.5 million gross, or $4.1 million net, through warrant exercises and a private placement.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major pointApproximately $4.1 million net financing proceeds secured in August 2026 to support clinical and preclinical development. 3.3× market cap
- Moderate pointNet loss narrowed to $6.5 million in third-quarter 2026, versus $7.5 million a year earlier.
- Moderate point. Forward-looking: it has not happened yet and may not happen.RAINIER Phase 1b completion targeted by year-end 2026; regulatory interaction planned for first-half 2027.
- Minor pointEleven of 14 evaluable TP53-mutated patients achieved remission with mipletamig combination therapy, including nine complete remissions.
- Minor point79% remission rate compares with a published 41% historical benchmark in a different, intent-to-treat population.
6 minor points
- Minor point13 of 14 evaluable TP53-mutated patients (93%) experienced clinical benefit, including remission and other responses.
- Minor pointTen of 47 evaluable frontline patients receiving mipletamig combination therapy proceeded to potentially curative stem cell transplantation.
- Minor pointInfusion-related reactions decreased following mipletamig priming-dose refinements, Aptevo reported.
- Minor pointManufacturing optimization progressed for next-generation trispecific candidates toward human testing.
- Minor pointNew patent application covers Nectin-4 × PD-L1 dual-targeting technology for potential immune therapies and radiopharmaceuticals.
- Minor point. Forward-looking: it has not happened yet and may not happen.Up to $22.5 million additional proceeds possible if newly issued warrants are exercised.
Negative
- Major point254,922 warrant-exercise shares and 861,708 additional shares or pre-funded warrants at $4.03 per share dilute holders.
- Moderate pointCash declined to $8.3 million at September 30, 2026, from $9.8 million at June 30.
- Minor point. Forward-looking: it has not happened yet and may not happen.New warrants covering up to 5,583,150 shares at $4.03 per share create potential further dilution.
- Minor point$0.4 million issuance costs reduced August financing proceeds.
Key Figures
- Clinical benefit rate
- 13 of 14 patients (93%)
- TP53-mutated AML patients treated with mipletamig, venetoclax and azacitidine
- CR/CRi rate
- 11 patients (79%)
- TP53-mutated patients treated with the mipletamig triplet
- Published composite remission benchmark
- 41%
- Intent-to-treat, treatment-naive patients with poor-risk cytogenetics and TP53-mutated AML receiving venetoclax plus azacitidine
- Advanced to stem cell transplantation
- 10 of 47 evaluable patients
- Frontline patients treated with mipletamig combination therapy
- RAINIER and regulatory milestones
- Study completion targeted by year-end 2026; regulatory interaction planned for the first half of 2027
- Mipletamig development
- Cash and cash equivalents
- $8.3 million, compared with $9.8 million
- September 30, 2026, compared with June 30, 2026
- Net loss
- $6.5 million, compared with $7.5 million
- Third quarter 2026 compared with third quarter 2025
- August financing proceeds
- Approximately $4.5 million gross; approximately $4.1 million net
- Warrant inducement and private placement
Previous Earnings Reports
-
RAINIER reported 81% remission among 31 evaluable frontline AML patients; cash was $9.8 million.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
acute myeloid leukemia medical
allogeneic stem cell transplantation medical
orphan drug designation regulatory
investigational new drug regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
SEATTLE, WA / ACCESS Newswire / November 16, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, today reported financial results for the quarter ended September 30, 2026, and highlighted new clinical findings supporting mipletamig's potential in frontline acute myeloid leukemia (AML), progress in optimizing treatment tolerability, and continued advancement of its next-generation cancer treatment pipeline.
"We are entering an exciting period for Aptevo, with growing clinical evidence that reinforces our confidence in mipletamig and meaningful progress across our broader pipeline," said Jeff Lamothe, President and Chief Executive Officer of Aptevo. "We are seeing strong clinical activity in patients with some of the most difficult-to-treat forms of AML, patients advancing to potentially curative stem cell transplantation, and important improvements in tolerability. Each of these findings adds a new dimension to the mipletamig story and strengthens our conviction in its potential to become an important addition to frontline AML treatment. At the same time, we are advancing a new generation of cancer therapies designed to bring the power of our multispecific technology to more patients and more types of cancer. As we approach important clinical and development milestones, we believe Aptevo is increasingly well positioned to translate the strength of our science into meaningful opportunities for patients and long-term value for shareholders."
Business Highlights
- Mipletamig delivers a
79% remission rate in one of the hardest-to-treat forms of AML, nearly double a published historical benchmark. In September, Aptevo reported that 14 evaluable TP53-mutated patients treated with mipletamig in combination with venetoclax and azacitidine, including two patients from the previously completed dose expansion trial, 13 (93% ) experienced clinical benefit. * Eleven patients achieved CR or CRi (79% ), including nine complete remissions.
*Clinical benefit includes complete remission (CR), complete remission with incomplete hematologic recovery (CRi), partial response (PR) and morphologic leukemia-free state (MLFS).
These results are encouraging because patients with TP53-mutated AML have historically had limited treatment success. The
**Benchmark comparison based on Pollyea DA, et al. Clinical Cancer Research. 2022;28(24):5272-5279. Comparison is to treatment-naïve patients with poor-risk cytogenetics and TP53-mutated AML treated with venetoclax plus azacitidine.
- Ten of 47 patients receiving mipletamig combination therapy advances to potentially curative stem cell transplantation. In October, Aptevo reported that ten of 47 evaluable frontline patients treated with mipletamig in combination with venetoclax and azacitidine (VEN+AZA) proceeded to allogeneic stem cell transplantation, a potentially curative treatment option. This includes nine patients from the ongoing Phase 1b RAINIER trial and one patient from the previously completed dose expansion trial. This finding is particularly encouraging in a patient population initially deemed unfit for intensive induction chemotherapy, where advanced age, underlying health conditions and other factors can limit treatment options.
- Aptevo significantly reduced infusion-related reactions through refinements to mipletamig's priming-dose regimen. The adjustment substantially improved tolerability, addressing an important clinical development priority. For patients already facing the challenges of AML treatment, fewer reactions may mean a more manageable treatment experience, while supporting continued advancement toward Phase 2.
- Mipletamig approaches a major development milestone as RAINIER nears completion of Phase 1b dose optimization. With study completion targeted by year-end 2026 and regulatory interaction planned for the first half of 2027, Aptevo is moving closer to the next phase of clinical development, bringing mipletamig another step toward its potential role in frontline AML treatment.
- Aptevo clears important development hurdles on the path toward human testing of its next generation trispecifics. Progress in manufacturing optimization supports the ability to produce therapeutics that perform more than one immune engaging job in a single molecule - reliably and at the scale needed for further development. This moves Aptevo closer to advancing new treatment candidates for solid tumors, expanding its opportunities beyond AML.
- Aptevo expands the potential of its technology to power multiple new cancer treatments. A new patent application covering Nectin-4 × PD-L1 dual-targeting technology could support both immune-based therapies and radiopharmaceuticals. The filing strengthens Aptevo's intellectual property strategy, creating opportunities to apply its technology across multiple cancer treatment approaches.
- Aptevo secures
$4.5 million in additional financing to support its next development milestones. In August, existing warrant holders exercised warrants for 254,922 shares at a price of$4.03 per share and purchased 861,708 additional shares (or pre-funded warrants) at the same price in a private placement. Investors also received new warrants covering up to 5,583,150 shares at$4.03 per share, which would provide up to$22.5 million in additional proceeds if exercised. The transaction provides additional capital to advance mipletamig and the Company's next-generation pipeline, helping fund continued clinical and preclinical progress.
Third Quarter 2026 Financials
- Cash position: Cash and cash equivalents totaled
$8.3 million as of September 30, 2026, compared with$9.8 million as of June 30, 2026. - Net loss: Net loss for the third quarter of 2026 was
$6.5 million , compared with$7.5 million for the third quarter of 2025. - Financing activity: In August 2026, the company completed a warrant inducement and private placement that generated gross proceeds of approximately
$4.5 million , or approximately$4.1 million net of$0.4 million in issuance costs. - For additional APVO financial information and complete access to the company's filings, click here.
About Aptevo
Aptevo Therapeutics Inc. (Nasdaq:APVO) is a clinical-stage biotechnology company focused on developing novel bispecific and trispecific immunotherapies for the treatment of cancer. The Company's lead clinical candidate, mipletamig, is currently being evaluated in RAINIER, a two-part Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard-of-care venetoclax and azacitidine. Mipletamig has received orphan drug designation for AML under the Orphan Drug Act.
In the solid tumor space, Aptevo's lead assets are focused on well-established targets to progress novel immunomodulatory platform backbones that are conditionally active only in the tumor.
This work includes advancing APVO451, a targeted trispecific immunotherapy candidate for solid tumors, and a strategic collaboration with Niowave to develop up to three radiopharmaceutical oncology programs. The first radiopharmaceutical program is expected to target nectin-4, a tumor-associated antigen expressed in multiple solid tumor types. Both preclinical molecules are expected to advance into investigational new drug (IND)-enabling studies in 2027.
The Company's eight pipeline candidates are created using its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platforms, which are designed to generate differentiated multispecific therapeutics. For more information, please visit www.aptevotherapeutics.com.
Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, without limitation, statements regarding Aptevo's expectations about the activity, efficacy, safety, tolerability and durability of mipletamig, including in combination with venetoclax and azacitidine; statements related to the progress of the RAINIER trial, including statements related to anticipated clinical and regulatory milestones; statements related to a growing number of patients treated with the mipletamig triplet advancing to stem cell transplant and mipletamig's role in offering AML patients the possibility of long-term remission or cure, statements related to the responses observed in patients with TP53-mutated AML and whether further study of mipletamig in combination with venetoclax + azacitidine will continue to show clinical benefit in patients with TP53-mutated AML; whether Aptevo's strategy will translate into an improved overall survival rate in acute myeloid leukemia (AML); whether the mipletamig data in combination therapy will be indicative of later stage clinical trials; whether Aptevo's strategy will translate into improved overall survival in AML, especially among patient subgroups with poor prognosis; its expectations regarding the effectiveness of its ADAPTIR and ADAPTIR-FLEX platform; development and continued development of Aptevo's current and potential future molecules, including Aptevo's trispecific candidates and their future development and efficacy with respect to addressing multiple solid tumor types; whether pre-clinical studies of Aptevo's trispecific candidates will show the desired anti-tumor efficacy, mechanism of action and safety profile and whether Aptevo's trispecific candidates will function with new mechanisms of action compared to our previous candidates and synergistically induce a biological response; the potential benefits, timing, scope and outcomes of the co-development collaboration with Niowave; and any statements containing the words "may," "continue to," "believes," "expects," "potential," "designed," "promising," "plans," "will" and similar expressions are intended to identify forward-looking statements.
These forward-looking statements are based on Aptevo's current intentions, beliefs and expectations regarding future events. Aptevo cannot guarantee that any forward-looking statement will be accurate. Investors are cautioned not to place undue reliance on any forward-looking statement. There are several important factors that could cause Aptevo's actual results to differ materially from those indicated by such forward-looking statements, including a deterioration in Aptevo's business or prospects; further assessment of preliminary or interim data or different results from later clinical trials; adverse events and unanticipated problems; adverse developments in clinical development, including unexpected safety issues observed during a clinical trial; and changes in regulatory, social, macroeconomic and political conditions. Additional risks and factors that may affect results are set forth in Aptevo's filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2026, and its subsequent reports on Form 10-Q and current reports on Form 8-K. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, Aptevo does not assume any obligation to update any forward-looking statement to reflect new information, events or circumstances.
CONTACT:
Miriam Weber Miller
Vice President, Investor Relations & Corporate Communications
Aptevo Therapeutics
Email: IR@apvo.com or Millerm@apvo.com
Phone: 206-859-6628
SOURCE: Aptevo Therapeutics
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Aptevo's mipletamig combination show in TP53-mutated AML patients?
Among 14 evaluable patients, 11 achieved complete remission or complete remission with incomplete blood-count recovery, a 79% rate; nine had complete remissions. Thirteen patients experienced clinical benefit. The group included two patients from the previously completed dose expansion trial.
When does Aptevo expect to complete RAINIER Phase 1b dose optimization?
Aptevo targets study completion by year-end 2026 and plans regulatory interaction in the first half of 2027.
How does the historical benchmark for Aptevo's mipletamig remission results differ from its patient group?
The published 41% composite remission benchmark covers intent-to-treat, treatment-naïve patients with poor-risk cytogenetics and TP53-mutated AML receiving venetoclax plus azacitidine. Aptevo's 79% result covers evaluable TP53-mutated patients receiving mipletamig with those drugs.
Which trials supplied Aptevo's mipletamig patients who proceeded to stem cell transplantation?
Of the ten patients who proceeded to transplantation, nine came from the ongoing Phase 1b RAINIER trial and one from the previously completed dose expansion trial. These frontline patients were initially deemed unfit for intensive induction chemotherapy.